Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
about
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEACantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic studyCA 242 is a new tumor marker for pancreatic cancer.Eradication of large colon tumor xenografts by targeted delivery of maytansinoidsMonoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice.Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancerComparative study of CA242 and CA19-9 in chronic pancreatitis.A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate dClinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study
P2860
Q24678824-196E4580-C47C-486F-887C-CF6717295E3EQ28270259-B2533652-FB4C-4588-BF6E-4ED9CE477402Q34360290-D0222FA3-A031-4F84-AA4C-F6A3F2AE6BEDQ34389426-A3B13E4C-4820-4D0C-BAF8-125FD8922FCBQ35604941-AA2F6F6C-5BDD-478B-A2A8-3144FB43D2ACQ35976947-EC9C8613-55AC-45E4-AAA8-655E7B038963Q36079626-F7D27E89-D2FC-428A-A02C-2B4B1DE55E27Q39993160-B604EDD8-A6BF-4717-860E-FEC76FC79849Q41960323-0FF4FA4A-4424-476D-98F7-8509C4B3279CQ42023730-B5B56E52-0B19-466A-800A-21FC1ECB2277Q42372132-79D9E618-A2B5-4C75-AAB3-D3192C203AE0Q42390240-1B3E802F-87F4-49A3-A8E4-E96B5275080C
P2860
Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Tissue expression of the tumou ...... arison with CA 50 and CA 19-9.
@en
Tissue expression of the tumou ...... arison with CA 50 and CA 19-9.
@nl
type
label
Tissue expression of the tumou ...... arison with CA 50 and CA 19-9.
@en
Tissue expression of the tumou ...... arison with CA 50 and CA 19-9.
@nl
prefLabel
Tissue expression of the tumou ...... arison with CA 50 and CA 19-9.
@en
Tissue expression of the tumou ...... arison with CA 50 and CA 19-9.
@nl
P2093
P2860
P356
P1476
Tissue expression of the tumou ...... arison with CA 50 and CA 19-9.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1989.377
P407
P577
1989-12-01T00:00:00Z